Vitamin D deficiency and diabetes mellitus are both global health concerns with increasing prevalence. Recent research suggests a potential link between vitamin D status and the development and progression of various types of diabetes. This review aims to analyse the clinical evidence on the relationship between vitamin D supplementation and glycaemic control across different populations: individuals with prediabetes, type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes mellitus (GDM). A systematic search of randomised clinical trials (RCTs) published from 2014 to 2024 was conducted in PubMed, Scopus, and Web of Science. Sixteen studies met the inclusion criteria. The findings were mixed. In prediabetes, vitamin D improved serum 25(OH)D levels, but effects on glycaemic parameters were inconsistent. In T1D, supplementation was associated with reduced insulin requirements and improved C-peptide levels, especially in children with vitamin D deficiency. T2D results were variable: some trials reported improvements in HbA1c and HOMA-IR, while others found no significant changes. In GDM, supplementation improved fasting insulin response and reduced adverse pregnancy outcomes. Overall, vitamin D supplementation shows potential benefits in certain contexts, particularly in T1D and GDM. However, heterogeneity in dosage, duration, and baseline characteristics limits the generalisability of findings. Further high-quality RCTs are needed to define optimal regimens and identify subpopulations most likely to benefit.

Human papillomavirus (HPV) is a major cause of several cancers, most notably cervical cancer, which is the fourth most common cancer in women worldwide.HPV infections are typically spread through skin-to-skin contact during sexual activity, and while most infections are cleared by the immune system without symptoms, persistent infection with high-risk strains, such as HPV-16 and HPV-18, can lead to cellular changes in the body.These changes, over time, can result in precancerous lesions and, if untreated, progress to invasive cancer.Human papillomavirus (HPV) is a prevalent sexually transmitted infection recognised as the primary cause of cervical cancer, as well as other malignancies such as anal, oropharyngeal, penile, vulvar, and vaginal cancers.Recent advancements in HPV vaccines, including broader protection against multiple strains, have significantly contributed to reducing the incidence of HPV-related cancers.This review explores the role of HPV in oncogenesis, focusing on its types, mechanisms, and contribution to various cancers.Current prevention strategies, including vaccination, screening, and treatment options, are also discussed.The article emphasises the importance of widespread vaccination and early detection to reduce the global burden of HPV-associated cancers.

Heart failure (HF) is a progressive clinical syndrome that affects millions of people worldwide and significantly contributes to morbidity and mortality.The condition presents as inadequate blood supply to comply with the body's oxygen requirements because of inefficient heart function.Underlying comorbidities such as hypertension, diabetes, and structural heart disease can cause progressive heart failure.HF can be divided into three primary categories: heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF).Each type presents unique challenges regarding diagnosis and treatment, necessitating tailored clinical strategies.Pharmacological therapies such as ACE-inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential in the management of heart failure.Non-pharmacological interventions like lifestyle modifications, smoking cessation and dietary management are important.The significance of a multidisciplinary approach, particularly in enhancing long-term outcomes and quality of life in the management of HF are important.Effective management of heart fHF requires a balance between adherence to clinical guidelines and the provision of individualised care.By integrating evidence-based medicine with comprehensive patient support, healthcare providers can more effectively address the complexities of HF, enabling patients to manage their condition with increased confidence and dignity.This article examines the fundamental aspects of HF, including its pathophysiology, classification, and symptoms, while underscoring the critical need for early diagnosis and patient-centred care, through a multidisciplinary approach.